Overview

A Phase 2a, Dose-Ranging Study to Evaluate the Safety, Pharmacokinetics and Efficacy of VX-135 With Ribavirin in Treatment-Naïve Subjects With Chronic Hepatitis C

Status:
Completed

Trial end date:
2014-06-30

Target enrollment:

Participant gender:

Summary

The purpose of the study is to determine the safety, pharmacokinetics and efficacy of orally administered VX-135 with ribavirin in treatment naive subjects with chronic hepatitis C infection.

Phase:

Phase 2

Details

Lead Sponsor:

Alios Biopharma Inc.

Collaborator:

Vertex Pharmaceuticals Incorporated

Treatments:

Ribavirin